PPT-Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir

Prepared by Sophie Woolston MD and David H Spach MD Last Updated November 18 2014 3D Background and Dosing 3D Paritaprevir Ritonavir Ombitasvir Dasabuvir 3D Paritaprevir. PTV150/r + OBV + . DSV . + RBV. PTV150/r + . DSV . + RBV. 2-steps. Randomisation*. Open-label. W12. W8. W24. 18-70 years. Chronic HCV infection . Genotype 1. HCV RNA ≥ 50,000 IU/ml. Treatment-naïve . TURQUOISE-II. Phase 3. . Treatment. Naïve and Treatment . Experienced. Poordad. F, et al. N . Engl. J Med. 2014;370:1973-82.. Compensated Cirrhosis. Source: . Poordad. F, et al. N . Engl. J Med. 2014;370:1973-82.. Out With the Old, In With the New. Current Standard of Care. NEUTRINO and FISSION. . SOF + RBV ± pegIFN for Treatment-naive Patients. NEUTRINO and FISSION. . SOF + RBV ± pegIFN for Treatment-naive Patients. -Ritonavir. -Ombitasvir . + Dasabuvir) . + RBV in . GT1. SAPPHIRE-II. Phase . 3. Treatment. . Experienced. Zeuzem. S, . et al. N . Engl. J Med. . 2014;370:1604-14.. Source: . Zeuzem. S, et al. N . Co-formulated . ombitasvir. (OBV)/. paritaprevir. (PTV)/. rironavir. (r) :. 25/150/100 mg QD = 2 tablets. Dasabuvir. (DSV) : 250 mg bid. Objective. SVR. 12. (HCV RNA < 25 IU/ml). TURQUOISE-III . SAPPHIRE-I. Phase 3. . Treatment. . Naïve. Feld JJ, et al. N . Engl. J Med. 2014;370:1594-1603.. Source: Feld JJ, et al. N . Engl. J Med. 2014;370:1594-1603.. 3D . (Paritaprevir-Ritonavir-. Ombitasvir + Dasabuvir) + Ribavirin in GT1. . and Dasabuvir +/- . RBV in . GT1b. PEARL-II. Phase . 3. Treatment. . Experienced. Andreone. P, . et al. . Gastroenterology. 2014;147:359-65.. Source: . Andreone. P, et al. Gastroenterology. 2014;147:359-65.. Paritaprevir. -. Ritonavir. . and . Dasabuvir. +/- RBV in GT1. PEARL-III and PEARL-IV. Phase 3. . Treatment. . Naïve. Ferenci. P, et al. N . Engl. J Med. 2014;370:1983-92.. Source: . Ferenci. . . + Dasabuvir) + RBV in GT1 . TURQUOISE-I. Phase . 2 . Treatment. Naïve and Treatment . Experienced. Wyles. D, et al. 65. th. AASLD. 2014: Abstract . 1939. . . HIV Coinfection. Source: . Wyles. D, et al. 65. Updated: . July . 6. , . 2015. Treatment of Hepatitis C in Patients with Renal Insufficiency. Robert G. Gish MD. Professor Consultant, Stanford University Medical Center. Senior Medical Director, St Josephs Hospital and Medical Center, Liver Program, Phoenix, Arizona. Drug-Resistant . HIV. Study . 0105. Activity of Elvitegravir Against Drug-Resistant HIV. Study 0105: Design. Source: . Zolopa. A, et al. J Infect Dis. 2010;201:814-22.. Elvitegravir . (20 mg). . + . AI424-043 . Study. Atazanavir vs. Lopinavir-ritonavir in Previous PI Failure . AI424-043. : Study Design. Source: . Cohen C, et al. . Curr Med Res Opin. . 2005;21:. 1683-92.. Atazanavir 400 mg once daily + 2 NRTIs. Ombitasvir + . Dasabuvir) +/- . RBV in . GT1b. PEARL-II. Phase . 3. Treatment. . Experienced. Andreone. P, . et al. . Gastroenterology. 2014;147:359-65.. Source: . Andreone. P, et al. Gastroenterology. 2014;147:359-65.. R. itonavir to Raltegravir. SWITCHMRK 1 & 2 Trials. Switching from Lopinavir-Ritonavir to Raltegravir. SWITCHMRK 1 & 2 Trials: Study Design. Source: . Eron. JJ, et al. Lancet. 2010;375:396-407..